Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

330
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
330
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

360
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
360
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

306
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
306
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

307
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
307

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biosimilars approved for hematologists: lessons from comparative efficacy studies and comparative analytical assessments.

Blood·2026
Same author

FDA's Regulatory Reforms to Unlock Competition and Lower Drug Costs: Breaking the Biosimilar Bottleneck.

JAMA·2026
Same author

Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death.

Cancer cell·2025
Same author

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.

Journal of immunotherapy and precision oncology·2025
Same author

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).

Future oncology (London, England)·2024
Same author

A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.

Future oncology (London, England)·2024
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Camrelizumab, a patinib and radiotherapy in locally advanced, unresectable hepatocellular carcinoma: a phase 2 study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

FDA's Approach to Regulating Biosimilars.

Steven J Lemery1, M Stacey Ricci2, Patricia Keegan3

  • 1Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. Steven.lemery@fda.hhs.gov.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 31, 2016
PubMed
Summary
This summary is machine-generated.

Biosimilar products are highly similar to reference biologics, with no clinically meaningful differences in safety, purity, or potency. Regulatory approval ensures biosimilars meet rigorous FDA standards for safety and efficacy, comparable to reference products.

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

2.0K

Related Experiment Videos

Last Updated: Mar 9, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

2.0K

Area of Science:

  • Pharmaceutical Science
  • Regulatory Science
  • Biotechnology

Background:

  • The Biologics Price Competition and Innovation (BPCI) Act established a regulatory pathway for biosimilars in the United States.
  • Biosimilars are biological products highly similar to FDA-licensed reference products, with no clinically meaningful differences.
  • The U.S. Food and Drug Administration (FDA) regulates biosimilars based on the BPCI Act requirements.

Purpose of the Study:

  • To outline the FDA's regulatory framework for biosimilar and interchangeable biological products.
  • To explain the scientific and regulatory standards for demonstrating biosimilarity.
  • To assure healthcare professionals and patients about the safety and efficacy of biosimilars.

Main Methods:

  • The development of biosimilars relies on analytical similarity assessments comparing structural, physicochemical, and functional properties.
  • Clinical studies, including immunogenicity and pharmacokinetic/pharmacodynamic assessments, evaluate for clinically meaningful differences.
  • The FDA's rigorous standards for safety and efficacy must be met for biosimilar approval.

Main Results:

  • Biosimilar products are demonstrated to be highly similar to their reference products.
  • Minor differences in inactive components are permissible if they do not impact safety, purity, or potency.
  • No clinically meaningful differences in safety, purity, and potency exist between biosimilars and reference products.

Conclusions:

  • Biosimilar products are approved based on a comprehensive data package demonstrating high similarity and no clinically meaningful differences.
  • Patients and healthcare providers can rely on the safety and effectiveness of biosimilars in the same way as reference products.
  • The regulatory pathway ensures that biosimilars provide safe, effective, and high-quality treatment options.